Efficacy of oral methotrexate in paediatric Crohn's disease: A multicentre propensity score study

Gut

Volumn 64, Issue 12, 2015, Pages 1898-1904

  Turner, Dan ^a   Doveh, Etti ^b   Cohen, Ayala ^b   Wilson, Michelle L ^c   Grossman, Andrew B ^d   Rosh, Joel R ^e   Lu, Ying ^f   Bousvaros, Athos ^f   Deslandres, Colette ^g   Noble, Angela ^g   Baldassano, Robert N ^d   Levine, Arie ^h   Lerner, Aaron ^b   Wilson, David C ^c   Griffiths, Anne M ⁱ  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF MONTREAL   (Canada)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; CHILD; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROPENSITY SCORE; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BODY HEIGHT; CHEMICALLY INDUCED; CHILD DEVELOPMENT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; BODY HEIGHT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; NAUSEA; PROPENSITY SCORE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84954243731     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307964     Document Type: Article

References (46)

1. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005;(1):CD003459.
2. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
3. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
4. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007;102:2804-12.
5. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998;132:830-5.
6. Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr 2007;44:427-30.
7. Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr 2009;48:526-30.
8. Willot S, Noble A, Deslandres C. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis 2011;17:2521-6.
9. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006;12:1053-7.
10. Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn's disease. Nat Rev Gastroenterol Hepatol 2009;6:513-23.
11. Levine A, Koletzko S, Turner D, et al. The ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795-806.
12. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn disease. Inflamm Bowel Dis 2007;13:424-30.
13. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med 1992;11:1305-19.
14. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985;107:317-29.
15. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008;27:2037-49.
16. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol 2006;163:1149-56.
17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
18. Fitzmaurice G. Confounding: propensity score adjustment. Nutrition 2006;22:1214-16.
19. Hullsiek KH, Louis TA. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics 2002;3:179-3.
20. Leon AC, Hedeker D. Quantile stratification based on a misspecified propensity score in longitudinal treatment effectiveness analyses of ordinal doses. Comput Stat Data Anal 2007;51:6114-22.
21. Oakes JM, Church TR. Invited commentary: advancing propensity score methods in epidemiology. Am J Epidemiol 2007;165:1119-21; discussion 22-3.
22. Senn S, Graf E, Caputo A. Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure. Stat Med 2007;26:5529-44.
23. Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007;297:278-5.
24. Sturmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59:437-47.
25. Sturmer T, Schneeweiss S, Rothman KJ, et al. Performance of propensity score calibration-a simulation study. Am J Epidemiol 2007;165:1110-18.
26. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat 2007;17:1-13; discussion 5-7, 9-21, 3-7 passim.
27. McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32:3388-414.
28. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-8.
29. Ho DE, Imai K, King G, et al. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Software 2011;42:1-28.
30. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73-81.
31. Hameed B, Jones H. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. Int J Rheum Dis 2010;13:e83-4.
32. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:1232-4.
33. Rozin A, Schapira D, Balbir-Gurman A, et al. Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002;61:756-7.
34. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
35. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38:1851-6.
36. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619-27.
37. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-9.
38. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-9.
39. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000;95:1730-4.
40. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31:645-8.
41. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
42. Teresi ME, Crom WR, Choi KE, et al. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987;110:788-92.
43. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983;43:2342-5.
44. Sun JH, Das KM. Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand. J Clin Gastroenterol 2005;39:751-6.
45. Stephens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005;40:445-9.
46. Wilson A, Patel V, Chande N, et al. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2013;37:340-5.